Organon & Co.

10-K & 10-Q Filings

Organon & Co. is a global health care company focused on improving the health of women through a diverse portfolio of products in women's health, biosimilars, and established brands. The company's women's health portfolio includes contraception and fertility products, such as Nexplanon, NuvaRing, Follistim AQ, and Elonva. Organon's biosimilars portfolio includes Hadlima, Brenzys, Renflexis, Aybintio, and Ontruzant. The company's established brands cover various therapeutic areas, including cardiovascular, respiratory, dermatology, bone health, and non-opioid pain management. Organon has six manufacturing sites and a global supply chain, employing approximately 10,000 people worldwide. The company's website is organon.com, and its ticker symbol is ORGN.

12 mos ending Dec 31, 202112 mos ending Dec 31, 202212 mos ending Dec 31, 20233 mos ending Mar 31, 20233 mos ending Mar 31, 2024CAGR %YoY %Revenue (+)
$6304.00
6174.00
6263.00
1538.00
1622.00
-0.33%5.46%Cost of Revenue (-)
$4775.00
5052.00
5590.00
1303.00
1386.00
8.20%6.37%Gross Profit (+)
$1529.00
1122.00
673.00
235.00
236.00
-33.66%0.43%Selling, General & Administrative (-)
$1668.00
1704.00
1893.00
435.00
431.00
6.53%-0.92%Research & Development (-)
$443.00
578.00
528.00
137.00
112.00
9.17%-18.25%Non-recurring Operating Expenses (-)
$3.00
28.00
62.00
4.00
23.00
354.61%475.00%Operating Expenses (-)
$2114.00
2310.00
2483.00
576.00
566.00
8.38%-1.74%Costs & Expenses (Total) (-)
$2382.00
4619.00
2515.00
580.00
1249.00
2.75%115.34%Operating Income/Loss (+)
$1529.00
1555.00
1242.00
376.00
373.00
-9.87%-0.80%Non-operating Income/Expense (+)
$
-11.00
-42.00
-9.00
-6.00
33.33%Interest Expense (-)
$
422.00
527.00
132.00
131.00
-0.76%Earnings before Tax (+)
$1529.00
1122.00
673.00
235.00
236.00
-33.66%0.43%Tax Expense (-)
$178.00
205.00
-350.00
58.00
35.00
-39.66%Income/Loss (Continuing Operations) (+)
$1351.00
917.00
1023.00
177.00
201.00
-12.98%13.56%Income/Loss (Discontinued Operations) (+)
$
Net Income/Loss (+)
$1351.00
917.00
1023.00
177.00
201.00
-12.98%13.56%Net Income/Loss (Common) (+)
$1351.00
917.00
1023.00
177.00
201.00
-12.98%13.56%EPS (Basic)
$5.33
3.61
4.01
0.70
0.78
-13.26%11.43%EPS (Diluted)
$5.31
3.59
3.99
0.69
0.78
-13.32%13.04%Weighted Avg Shares (Basic)
253.54
254.08
255.24
254.39
255.69
0.33%0.51%Weighted Avg Shares (Diluted)
254.19
255.17
256.27
256.17
258.36
0.41%0.86%Cash
$737.00
706.00
693.00
459.00
575.00
-3.03%25.27%Receivables
$1382.00
1475.00
1744.00
1445.00
1547.00
12.34%7.06%Inventory
$915.00
1003.00
1315.00
1121.00
1263.00
19.88%12.67%Other Assets (Current)
$726.00
747.00
756.00
755.00
811.00
2.05%7.42%Assets (Current)
$3760.00
3931.00
4508.00
3780.00
4196.00
9.50%11.01%Property, Plant & Equipment (Net)
$973.00
1018.00
1183.00
1055.00
1180.00
10.26%11.85%Goodwill & Intangibles
$5254.00
5252.00
5136.00
5224.00
5321.00
-1.13%1.86%Other Assets
$694.00
754.00
1231.00
704.00
1194.00
33.18%69.60%Assets (Non-current)
$6921.00
7024.00
7550.00
6983.00
7695.00
4.45%10.20%Assets (Total)
$10681.00
10955.00
12058.00
10763.00
11891.00
6.25%10.48%Accounts Payable
$1567.00
1316.00
1520.00
1188.00
1151.00
-1.51%-3.11%Debt (Current)
$9.00
8.00
9.00
8.00
9.00
0.00%12.50%Other Liabilities (Current)
$1021.00
1188.00
1389.00
1150.00
1385.00
16.64%20.43%Liabilities (Current)
$2597.00
2512.00
2918.00
2346.00
2545.00
6.00%8.48%Debt (Non-current)
$9125.00
8905.00
8751.00
8703.00
8705.00
-2.07%0.02%Other Liabilities
$467.00
430.00
459.00
451.00
593.00
-0.86%31.49%Liabilities (Non-current)
$9592.00
9335.00
9210.00
9154.00
9298.00
-2.01%1.57%Liabilities (Total)
$12189.00
11847.00
12128.00
11500.00
11843.00
-0.25%2.98%Retained Earnings
$-998.00
-331.00
443.00
-206.00
573.00
378.16%AOCI
$-513.00
-564.00
-541.00
-534.00
-577.00
-8.05%Shareholder's Equity
$-1508.00
-892.00
-70.00
-737.00
48.00
106.51%Liabilities & Equity
$10681.00
10955.00
12058.00
10763.00
11891.00
6.25%10.48%Net Income/Loss
$
201.00
Depreciation & Amortization
$195.00
212.00
236.00
57.00
65.00
10.01%14.04%Increase/Decrease in Working Capital
$-702.00
452.00
155.00
163.00
223.00
36.81%Share-based Compensation
$59.00
75.00
101.00
22.00
26.00
30.84%18.18%Adjustments to Reconcile Net Income
$809.00
-59.00
-224.00
-63.00
-125.00
-98.41%Net Cash (Operating)
$2160.00
858.00
799.00
114.00
76.00
-39.18%-33.33%Capital Expenditure
$481.00
420.00
260.00
54.00
96.00
-26.48%77.78%Net Cash (Investing)
$-481.00
-420.00
-260.00
-54.00
-96.00
-77.78%Increase/Decrease in Debt
$7846.00
-108.00
-258.00
-252.00
-2.00
99.21%Increase/Decrease in Equity
$-118.00
Dividends Paid
$145.00
290.00
294.00
73.00
70.00
42.39%-4.11%Net Cash (Financing)
$-977.00
-433.00
-569.00
-326.00
-74.00
77.30%Effect of Exchange Rate
$23.00
-36.00
17.00
19.00
-24.00
-14.03%-226.32%Increase/Decrease in Cash
$667.00
-31.00
-13.00
-247.00
-118.00
52.23%Cash (Beginning)
$70.00
737.00
706.00
706.00
693.00
217.58%-1.84%Cash (Ending)
$737.00
706.00
693.00
459.00
575.00
-3.03%25.27%NOPAT
$1351.00
1270.89
1887.91
283.20
317.68
18.21%12.18%Gross Margin %
24.25%
18.17%
10.75%
15.28%
14.55%
Operating Margin %
24.25%
25.19%
19.83%
24.45%
23.00%
NOPAT Margin %
21.43%
20.58%
30.14%
18.41%
19.59%
Net Margin %
21.43%
14.85%
16.33%
11.51%
12.39%
Tax Rate %
11.64%
18.27%
-52.01%
24.68%
14.83%
ROA
12.65%
11.60%
15.66%
2.63%
2.67%
ROE
-89.59%
-142.48%
-2697.02%
-38.43%
661.84%
ROIC
19.09%
17.05%
24.24%
3.91%
4.16%
Asset Turnover
0.59
0.56
0.52
0.14
0.14
Inventory Turnover
5.22
5.04
4.25
1.16
1.10
Equity Multiplier
-7.08
-12.28
-172.26
-14.60
247.73
Current Ratio
1.45
1.56
1.54
1.61
1.65
Quick Ratio
0.82
0.87
0.84
0.81
0.83
Debt/Equity Ratio
-6.06
-9.99
-125.14
-11.82
181.54
Working Capital/Sales
0.13
0.19
0.23
0.62
0.70
R&D/Sales
0.07
0.09
0.08
0.09
0.07
Dividend Payout Ratio %
10.73%
22.82%
15.57%
25.78%
22.03%
Total Payout
$-7583.00
398.00
552.00
325.00
72.00
-77.85%Payout Ratio %
-561.29%
31.32%
29.24%
114.76%
22.66%